Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT). Detailed Description: Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
- 20 novembre 2024 - 1 mn de lecture
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT). Detailed Description: Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.
En rapport Clinical Trials
20 novembre 2024
1 mn de lecture
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
20 novembre 2024
1 mn de lecture
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
20 novembre 2024
1 mn de lecture
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
20 novembre 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
20 novembre 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Follow-on Study
20 novembre 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Study
20 novembre 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Study
20 novembre 2024
1 mn de lecture
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
20 novembre 2024
1 mn de lecture
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
20 novembre 2024
1 mn de lecture